05.22.18
Corbus Pharmaceuticals Holdings has appointed Robert Discordia, Ph.D., as vice president, Pharmaceutical Development & Manufacturing, and Ross Lobell as vice president, Regulatory Affairs. Dr. Discordia will oversee all aspects of Corbus’ chemistry, manufacturing and controls (CMC) for lenabasum and future drug candidates. Mr. Lobell will lead Corbus’ Regulatory Affairs and Quality Assurance groups.
“We are delighted to welcome Robert and Ross to the Corbus team. We look forward to their important contributions to steering lenabasum through its remaining clinical development, potential approval and commercialization,” stated Yuval Cohen, Ph.D., chief executive officer of Corbus.
Dr. Discordia brings to Corbus more than 25 years of biopharmaceutical industry experience in CMC development and business operations, and joins from Bristol-Myers Squibb where he most recently served as Executive Director, Business Operations, Procurement for Global Product Development & Supply.
Mr. Lobell is an expert in regulatory affairs with an extensive biopharmaceutical background in leading preclinical, clinical and nonclinical regulatory strategies and operations. Prior to his appointment at Corbus, he held various leadership positions across several global pharmaceutical companies, including Schering-Plough, Pfizer, Amgen and MedImmune, a member of the AstraZeneca Group.
“We are delighted to welcome Robert and Ross to the Corbus team. We look forward to their important contributions to steering lenabasum through its remaining clinical development, potential approval and commercialization,” stated Yuval Cohen, Ph.D., chief executive officer of Corbus.
Dr. Discordia brings to Corbus more than 25 years of biopharmaceutical industry experience in CMC development and business operations, and joins from Bristol-Myers Squibb where he most recently served as Executive Director, Business Operations, Procurement for Global Product Development & Supply.
Mr. Lobell is an expert in regulatory affairs with an extensive biopharmaceutical background in leading preclinical, clinical and nonclinical regulatory strategies and operations. Prior to his appointment at Corbus, he held various leadership positions across several global pharmaceutical companies, including Schering-Plough, Pfizer, Amgen and MedImmune, a member of the AstraZeneca Group.